Scarica l'app Stockscreener
14.28
0.00%
0.0059
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$14.29
Aprire:
$14.29
Volume 24 ore:
4.52M
Relative Volume:
0.45
Capitalizzazione di mercato:
$4.48B
Reddito:
$571.16M
Utile/perdita netta:
$-38.10M
Rapporto P/E:
-116.60
EPS:
-0.1225
Flusso di cassa netto:
$-48.91M
1 W Prestazione:
-0.14%
1M Prestazione:
+0.28%
6M Prestazione:
+135.81%
1 anno Prestazione:
+47.62%
Intervallo 1D:
$14.28
$14.29
Intervallo di 1 settimana:
$14.27
$14.36
Portata 52W:
$5.51
$14.38
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.29 | 4.48B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.55 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.20 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.58 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.87 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.08 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-22 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-29 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-12-22 | Downgrade | TD Cowen | Buy → Hold |
| 2025-12-17 | Iniziato | Citigroup | Buy |
| 2025-09-18 | Aggiornamento | Needham | Hold → Buy |
| 2025-07-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Market Recap: What is the long term forecast for Amicus Therapeutics Inc stockMarket Growth Report & Weekly High Momentum Picks - baoquankhu1.vn
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders - marketscreener.com
Amicus Therapeutics CEO Campbell sells $1.07 million in shares By Investing.com - Investing.com Canada
Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Sells 75,000 Shares - TradingView
How the $4.8B Amicus deal with BioMarin came together - The Business Journals
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Amicus Therapeutics (FOLD): Jefferies Downgrades to Hold, Lowers Price Target | FOLD Stock News - GuruFocus
Jefferies downgrades Amicus Therapeutics stock to Hold on acquisition outlook - Investing.com Canada
How A New Price Target Is Shaping The Amicus Therapeutics (FOLD) Investment Story - Yahoo Finance
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission - Finviz
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies - Finviz
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease - Yahoo Finance
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus - TradingView
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
Amicus Therapeutics, Inc. $FOLD Holdings Boosted by Stephens Investment Management Group LLC - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - FinancialContent
Nordea Investment Management AB Makes New $7.84 Million Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Yahoo Finance
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Yahoo Finance
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit - Yahoo Finance
Amicus Therapeutics stock hits 52-week high at 14.36 USD By Investing.com - Investing.com Nigeria
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year HighHere's What Happened - MarketBeat
Amicus Therapeutics stock hits 52-week high at 14.36 USD - Investing.com
Aug Shorts: Is Amicus Therapeutics Inc. showing insider buyingWeekly Trade Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: 19.5% Revenue Growth and Potential Upside Attract Investors - DirectorsTalk Interviews
MDGL Secures Exclusive Global Right for MASH Treatment From PFE - Finviz
BioMarin Expands Rare Disease Portfolio With $4.8 Billion Amicus Acquisition - The Healthcare Technology Report.
BioMarin to acquire Amicus for $14.50 per share in cash, or $4.8B - MSN
Amicus Therapeutics : Legend (1) - marketscreener.com
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum - Yahoo Finance
Peregrine Capital Management LLC Acquires 72,178 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Why Amicus Therapeutics Inc. stock remains undervalued - Улправда
Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential - Yahoo Finance
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Will Amicus Therapeutics Inc. stock benefit from sector rotationPortfolio Value Report & Entry Point Strategy Guides - ulpravda.ru
How Amicus Therapeutics Inc. stock performs in rising dollar environment2025 Key Highlights & Weekly High Momentum Picks - ulpravda.ru
Risk Off: Can Amicus Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Risk Review & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Why retail investors pile into Amicus Therapeutics Inc. stockWatch List & Technical Buy Zone Confirmations - ulpravda.ru
Buyback Watch: Will Amicus Therapeutics Inc. stock remain a Wall Street favoriteWeekly Gains Summary & Risk Controlled Stock Alerts - ulpravda.ru
How Amicus Therapeutics Inc. stock compares to industry benchmarksSell Signal & Low Drawdown Investment Strategies - ulpravda.ru
Can Amicus Therapeutics Inc. stock deliver strong Q4 earningsMarket Activity Report & Growth Focused Investment Plans - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Yahoo Finance
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
San Gabriel Valley Tribune - FinancialContent
Amicus Therapeutics, Inc.Common Stock (NQ: FOLD - FinancialContent
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger-EKSO, FOLD, CWAN, and JHG - The Malaysian Reserve
Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.42%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):